I have recently been interested in MITF and its interaction with tyrosine kinase receptor family and performed several experiments using melanoma cell lines and xenograft model. However, according to the genetic database, solid tumors other than melanoma show the genetic change in MITF gene. The kind of genetic change largely depends on the tumor types as shown in the attached pdf, amplification tends to be highly detected in melanoma and esophageal cancer, while deletion in prostate cancer. Surely several reports focus on MITF in tumors other than melanoma, what kind of bone fide molecular regulation and pathological significance underlies in ectopic expression of MITF in tumors other than melanoma?